Edition:
India

Celsion Corp (CLSN.OQ)

CLSN.OQ on NASDAQ Stock Exchange Capital Market

1.82USD
23 Aug 2019
Change (% chg)

-- (--)
Prev Close
$1.82
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
17,247
52-wk High
$3.07
52-wk Low
$1.36

Latest Key Developments (Source: Significant Developments)

Celsion Announces IRB Approval To Begin A Clinical Study Of Thermodox
Thursday, 20 Jun 2019 

June 20 (Reuters) - Celsion Corp ::CELSION ANNOUNCES IRB APPROVAL TO BEGIN A CLINICAL STUDY OF THERMODOX PLUS HIGH INTENSITY FOCUSED ULTRASOUND IN BREAST CANCER PATIENTS AT UNIVERSITY MEDICAL CENTER UTRECHT IN THE NETHERLANDS.CELSION CORP - AN INVESTIGATOR-SPONSORED PHASE I SAFETY AND FEASIBILITY STUDY ESTIMATED TO BEGIN ENROLLMENT IN SECOND HALF OF 2019.CELSION CORP - STUDY FURTHER REINFORCES BROAD POTENTIAL OF THERMODOX TO TREAT A RANGE OF SOLID TUMORS WITH MULTIPLE LOCALIZED HEATING SOURCES.  Full Article

Celsion Corp Says Co And Egwu Entered Into An Amendment To That Certain Asset Purchase Agreement Dated As Of June 6, 2014
Monday, 1 Apr 2019 

April 1 (Reuters) - Celsion Corp ::CELSION CORP - ON MARCH 28, CO AND EGWU, INC. ENTERED INTO AN AMENDMENT TO THAT CERTAIN ASSET PURCHASE AGREEMENT DATED AS OF JUNE 6, 2014.CELSION-AMENDMENT PROVIDES PAYMENT OF OF $12.4 MILLION EARNOUT MILESTONE LIABILITY UNDER ASSET PURCHASE AGREEMENT RELATED TO OVARIAN CANCER INDICATION.CELSION CORP - AMENDMENT EXTENDS EARNOUT TERM FROM 7 YEARS TO 8 YEARS.CELSION-AS CONSIDERATION FOR ENTERING INTO AMENDMENT, ISSUED TO EGWU 200,000 WARRANTS TO PURCHASE COMMON STOCK WITH EXERCISE PRICE OF $0.01 PER SHARE.  Full Article

Celsion Reports PFS Data From GEN-1 Phase I Immuno-Oncology Study
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Celsion Corp ::CELSION ANNOUNCES PROGRESSION-FREE SURVIVAL DATA FROM GEN-1 PHASE I IMMUNO-ONCOLOGY STUDY OF PATIENTS WITH STAGE III/IV OVARIAN CANCER.CELSION CORP - STUDY DEMONSTRATED THAT GEN-1 IS WELL TOLERATED.CELSION CORP - ALL PATIENTS TREATED AT HIGHEST DOSE COHORT ACHIEVED COMPLETE SURGICAL RESECTION AFTER INTERVAL DEBULKING SURGERY.CELSION CORP - FIRST DATA ANALYSIS FROM PHASE I/II OVATION 2 STUDY IS EXPECTED IN FIRST HALF OF 2019.  Full Article

Celsion Corp Files For Mixed Shelf Of Up To $75 Million
Saturday, 8 Sep 2018 

Sept 7 (Reuters) - Celsion Corp ::CELSION CORP FILES FOR MIXED SHELF OF UP TO $75 MILLION – SEC FILING.  Full Article

Celsion Strengthens Its Balance Sheet With The Approval Of Its Application To Sell Net Operating Losses For Up To $10 Million In Non-Dilutive Funding
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - Celsion Corp ::PRESS RELEASE - CELSION STRENGTHENS ITS BALANCE SHEET WITH THE APPROVAL OF ITS APPLICATION TO SELL NET OPERATING LOSSES FOR UP TO $10 MILLION IN NON-DILUTIVE FUNDING.CELSION - CO ANTICIPATES TO TRANSFER CREDIT & RECEIVE UPTO $10 MILLION NET CASH PROCEEDS PRIOR TO 2018-END.  Full Article

Celsion Corp Announces Strategic Loan Facility
Thursday, 28 Jun 2018 

June 28 (Reuters) - Celsion Corp ::CELSION CORPORATION ANNOUNCES STRATEGIC LOAN FACILITY.CELSION CORP - ON JUNE 27, ENTERED INTO A $10 MILLION LOAN AGREEMENT WITH HORIZON TECHNOLOGY FINANCE CORPORATION.CELSION CORP - WILL USE FUNDING PROVIDED UNDER AGREEMENT FOR WORKING CAPITAL AND ADVANCEMENT OF ITS PRODUCT PIPELINE.  Full Article

Celsion Announces FDA Clearance Of The OVATION II Study For The Evaluation Of GEN-1 Immunotherapy
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Celsion Corp ::CELSION ANNOUNCES FDA CLEARANCE OF THE OVATION II STUDY FOR THE EVALUATION OF GEN-1 IMMUNOTHERAPY TO TREAT NEWLY DIAGNOSED STAGE III/IV OVARIAN CANCER.CELSION CORP - EXPECTS TO INITIATE ENROLLMENT OF PHASE I PORTION OF OVATION II STUDY IN FIRST HALF OF 2018.CELSION CORP - COMPANY EXPECTS TO HAVE 25% OF OVATION II STUDY ENROLLED BY END OF 2018.  Full Article

Celsion reports Q3 loss of $0.70/shr
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Celsion Corp :Celsion Corporation reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.70.  Full Article

CELSION ANNOUNCES PRICING OF COMMON STOCK OFFERING
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Celsion Corp ::CELSION CORPORATION ANNOUNCES PRICING OF UNDERWRITTEN OFFERING OF COMMON STOCK AND WARRANTS TO PURCHASE COMMON STOCK.‍PRICING OF OFFERING OF 2.64 MILLION SHARES OF COMMON STOCK, WARRANTS TO BUY UP TO 1.32 MILLION SHARES OF COMMON STOCK AT $2.50/SHARE, RELATED WARRANTS​.  Full Article